A prospective study found PSMA PET/CT-targeted biopsy detected more clinically significant prostate cancer than systematic biopsy in men with nondiagnostic MRI.
Brainomix reports Phase III INBUILD data on quantitative CT in 474 patients with progressive pulmonary fibrosis, examining treatment response and FVC decline.
USC researchers are developing a miniaturized PET radiotracer platform designed to simplify production, accelerate tracer development and expand molecular imaging applications.
Bayer reports Phase III results for investigational I 124 evuzamitide in cardiac amyloidosis, with primary endpoints met for visual PET scan interpretation.
Philips has received FDA 510(k) clearance for its Rembra imaging platform, including Rembra CT, Rembra RT and Areta RT, designed to support high-throughput CT imaging and radiation therapy planning across the cancer care pathway.
A session highlighting how amyloid, tau, and FDG PET sharpen Alzheimer’s diagnosis, support therapy decisions, and improve safety monitoring, marking a key advance in precision imaging.
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.